CN Patent
CN102015714B — 用于抗病毒治疗的1’-取代的carba-核苷类似物
Assigned to Gilead Sciences Inc · Expires 2014-09-24 · 12y expired
What this patent protects
提供了吡咯并[1,2-f][1,2,4]三嗪基、咪唑并[1,5-f][1,2,4]三嗪基、咪唑并[1,2-f][1,2,4]三嗪基和[1,2,4]三唑并[4,3-f][1,2,4]三嗪基核苷,核苷磷酸酯和其前药,其中所述核苷糖的1’位被取代。提供了可用于治疗黄病毒科病毒感染、尤其是丙型肝炎感染的化合物、组合物和方法。式(I)中各个X 1 或X 2 独立地是C-R 10 或N。 式I
USPTO Abstract
提供了吡咯并[1,2-f][1,2,4]三嗪基、咪唑并[1,5-f][1,2,4]三嗪基、咪唑并[1,2-f][1,2,4]三嗪基和[1,2,4]三唑并[4,3-f][1,2,4]三嗪基核苷,核苷磷酸酯和其前药,其中所述核苷糖的1’位被取代。提供了可用于治疗黄病毒科病毒感染、尤其是丙型肝炎感染的化合物、组合物和方法。式(I)中各个X 1 或X 2 独立地是C-R 10 或N。 式I
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.